

Attorney Docket No.: 5347.210-US

GLOBAL
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al

Confirmation No: 6030

Serial No.: 09/816721

Group Art Unit: 1652

Filed: March 22, 2001

Examiner: Rao

For: Novel Cyclomaltoextrin Glucanotransferase Variants

FAX RECEIVED

OCT 29 2002

GROUP 1600

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement
2. Preliminary Amendment

was sent to the United States Patent Office by telefax to the attention of Examiner Rao, fax number (703)308-4242.

Respectfully submitted,

Date: October 28, 2002


Julie Tabarovsky
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097



FAX COVER SHEET

No. of pages incl. this: 4

FAX RECEIVED

OCT 29 2002

GROUP 1600

Telefax no.: (703)308-4242

T : Examiner: M. Rao

From: Julie Tabarovsky

Date: October 28, 2002

Message:

OFFICIAL

The information contained in this facsimile message is legally privileged and confidential information intended solely for the use of the persons or entities named below. If you are not such persons or entities, you are hereby notified that any distribution, dissemination or reproduction of this facsimile message is strictly prohibited. If you have received this message in error, please immediately call us collect at the above number.

Novozymes
North America, Inc.
Patents-US
500 Fifth Avenue,
Suite 1600
New York, NY 10110

Telephone:
(212) 840-0097, ext. 10
Telefax:
(212) 840-0221

email:
JTab@novozymes.com
internet:
www.novozymes.com